Abstract
This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.
| Original language | English |
|---|---|
| Pages (from-to) | 1841-1848 |
| Number of pages | 8 |
| Journal | Future Oncology |
| Volume | 9 |
| Issue number | 12 |
| Publication status | Published - Dec 2013 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Eribulin in cutaneous breast cancer metastasis treatment : clinical activity and symptom control. / La Verde, Nicla; Moretti, Anna; Farina, Gabriella; Dazzani, Maria Chiara; Gamucci, Teresa; Borgonovo, Karen; Botta, Mario; Salesi, Nello; Zuradelli, Monica; Pavese, Ida; Barbieri, Elena; Cretella, Elisabetta; Saladino, Tiziana; Varese, Paola; Traverso, Elena Silvia; Addamo, Gianfranco; Ciccarese, Mariangela; Rispoli, Anna Iolanda; Pellegrino, Arianna; Mentuccia, Lucia; Girelli, Serena; Piva, Sheila; Di Maio, Massimo.
In: Future Oncology, Vol. 9, No. 12, 12.2013, p. 1841-1848.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Eribulin in cutaneous breast cancer metastasis treatment
T2 - clinical activity and symptom control.
AU - La Verde, Nicla
AU - Moretti, Anna
AU - Farina, Gabriella
AU - Dazzani, Maria Chiara
AU - Gamucci, Teresa
AU - Borgonovo, Karen
AU - Botta, Mario
AU - Salesi, Nello
AU - Zuradelli, Monica
AU - Pavese, Ida
AU - Barbieri, Elena
AU - Cretella, Elisabetta
AU - Saladino, Tiziana
AU - Varese, Paola
AU - Traverso, Elena Silvia
AU - Addamo, Gianfranco
AU - Ciccarese, Mariangela
AU - Rispoli, Anna Iolanda
AU - Pellegrino, Arianna
AU - Mentuccia, Lucia
AU - Girelli, Serena
AU - Piva, Sheila
AU - Di Maio, Massimo
PY - 2013/12
Y1 - 2013/12
N2 - This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.
AB - This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.
UR - http://www.scopus.com/inward/record.url?scp=84903686115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903686115&partnerID=8YFLogxK
M3 - Article
C2 - 24295414
AN - SCOPUS:84903686115
VL - 9
SP - 1841
EP - 1848
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 12
ER -